Evaxion Biotech A/S
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a EVAX research report →
Companywww.evaxion-biotech.com
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases.
- CEO
- Helen Katrina Tayton-Martin
- IPO
- 2021
- Employees
- 46
- HQ
- Horsholm, DK
Price Chart
Valuation
- Market Cap
- $25.27M
- P/E
- -3.41
- P/S
- 3.36
- P/B
- 1.96
- EV/EBITDA
- -0.85
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 100.00%
- Op Margin
- -122.24%
- Net Margin
- -129.81%
- ROE
- -77.90%
- ROIC
- -34.01%
Growth & Income
- Revenue
- $7.53M · 125.12%
- Net Income
- $-7,707,000 · 27.07%
- EPS
- $-1.21 · 87.65%
- Op Income
- $-9,234,000
- FCF YoY
- 48.56%
Performance & Tape
- 52W High
- $12.15
- 52W Low
- $1.68
- 50D MA
- $4.06
- 200D MA
- $4.38
- Beta
- 0.27
- Avg Volume
- 31.19K
Get TickerSpark's AI analysis on EVAX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 16, 26 | Bitsch-Norhave Jens | other | 0 |
| Mar 18, 26 | Mattsson Andreas Holm | other | 0 |
| Mar 18, 26 | Mattsson Andreas Holm | other | 0 |
| Jan 1, 22 | Mattsson Andreas Holm | other | 35,000 |
| Jan 1, 23 | Mattsson Andreas Holm | other | 6,250 |
| Jan 1, 24 | Mattsson Andreas Holm | other | 125,000 |
| Jan 1, 24 | Mattsson Andreas Holm | other | 25,000 |
| Dec 21, 23 | Mattsson Andreas Holm | other | 55,147 |
| Jan 31, 25 | Mattsson Andreas Holm | other | 645,700 |
| Mar 18, 26 | Soegaard Marianne | other | 0 |
Our EVAX Coverage
We haven't published any research on EVAX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate EVAX Report →